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Abstract
Background: An unmet medical need persists for elderly patients (pts) with
AML who are deemed not to be fit for intensive chemotherapy. Such pts are
usually treated with BSC and hydroxyurea or low-dose cytarabine, but
outcomes are dismal. The immunoconjugate GO has shown single agent
efficacy and tolerability in older pts with relapsed AML. The AML-19 study
was designed as a sequential phase II/III trial comparing GO monotherapy to
BSC (including hydroxyurea if clinically indicated) in pts age ≥ 61 yrs with
previously untreated AML who were considered unfit for intensive
chemotherapy (or refused it). Of the two induction schedules of GO (total
dose 9 mg/m delivered in 2 or 3 fractions over one week) under comparison
in the phase II part of the study, the 2-fraction regimen was found to have the
best efficacy profile to warrant phase III comparison with BSC (BJH 2010;
149:376). We herein report the final results of the phase III part of the study.
Methods: Untreated pts with de novo or secondary AML, adequate renal and
hepatic function, and WBC count <30x10 /L at baseline (a short course of
hydroxyurea permitted) were centrally randomized 1:1 (stratified by age,
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receive either a single induction course of GO (6 mg/m  day 1 and 3 mg/m
day 8) or BSC. Pts with no evidence of disease progression following GO
induction could receive up to 8 monthly infusions of the drug at 2 mg/m .
The primary objective of the study was to compare overall survival (OS) in the
two groups. A total of 210 deaths was required in order to detect a hazard
ratio (HR) of 0.63 for OS, with 90% power and 2-sided alpha=5%.
Results: Between 11/2004 and 03/2013, 237 pts were randomized from 35
European sites. The intention-to-treat population comprised 118 pts in the
GO arm and 119 in the BSC arm. The median age was 77 years (range 62-88)
with 64% of pts over 75 years. Baseline characteristics were well balanced
between arms. At the final analysis (05/2014 cutoff), 228 deaths occurred:
113/118 (95.8%) in the GO arm, and 115/119 (96.6%) in the BSC arm. GO
significantly improved OS (median 4.9 vs 3.6 months; 45.9% vs 29% alive at 6
months; 24.3% vs 9.7% alive at 1 year; 10.3% vs 6.9% alive at 1.5 year; HR,
0.69; 95% CI, 0.53-0.90; P=0.005) compared with BSC. Subgroup analyses
based on stratification factors and other baseline characteristics showed that
the OS benefit was generally consistent among subgroups, with a greater
effect seen in pts with good/intermediate cytogenetics (median 7.3 vs 3.8
months; HR, 0.48; 99% CI, 0.31-0.75), in those with high CD33 expression
(≥81% positive blasts; median 5.5 vs 3.8 months; HR, 0.47; 99% CI, 0.30-
0.74), as well as in those with secondary AML (median 7 vs 4 months; HR,
0.55; 99% CI, 0.33-0.91). Among 111 pts who received at least the first dose
of GO, the overall complete response rate was 27% (CR 15.3%, CRi 11.7%),
and the overall disease control rate (including PR in 5.4% and stable disease
for >30 days in 24.3%) was 56.7%. Of the 30 pts who achieved CR/CRi, 28
later relapsed or died in remission (1 infection, 2 general physical
deterioration, 2 unknown cause), and the median disease-free survival (DFS)
was 5.3 months with a 1-year DFS of 20%. CR/CRi pts had a median survival
from remission of 8.2 months, with 40% alive at 1 year. The 30-day all-cause
mortality from randomization was comparable in the GO (10.8%) and BSC
(13.5%) arms. Most frequent grade 3+ non-hematologic adverse events (AEs)
for GO vs BSC were infection (35.1% vs 34.3%), febrile neutropenia (18% vs
23.7%), bleeding (12.6% vs 12.3%), fatigue (11.7% vs 21%), and cardiac
toxicity (6.3% vs 14%). Severe liver dysfunction occurred infrequently (2.7% vs
1.8% for GO vs BSC), and no episodes of VOD were reported. Overall, AEs led
to GO discontinuation or death in 27 pts (24.3%).
Conclusions: Compared with BSC including hydroxyurea as necessary, single
agent GO in the dose/schedule chosen significantly improved OS in elderly
AML pts not considered fit for intensive chemotherapy, with an acceptable
safety profile. Of note, estimates of the benefit of GO were greater in pts
presenting with better-risk cytogenetics, high CD33 expression on blast cells,
or secondary disease.
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